Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04996160 · ClinicalTrials.gov registry record · Phase 1
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
A Phase 1 study of Refractory Acute Lymphoblastic Leukemia and Acute Lymphoblastic Leukemia, Pediatric, sponsored by Tanja Andrea Gruber.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT04996160 is a Phase 1 study of Refractory Acute Lymphoblastic Leukemia and Acute Lymphoblastic Leukemia, Pediatric that is actively recruiting participants, run by Tanja Andrea Gruber. The registered enrollment target is 22 participants, below the 44-participant average among 21 other Refractory Acute Lymphoblastic Leukemia trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04996160, a Phase 1 study of Refractory Acute Lymphoblastic Leukemia and Acute Lymphoblastic Leukemia, Pediatric, is actively recruiting participants, sponsored by Tanja Andrea Gruber.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
With this research study has following goals * To confirm the highest tolerable dose of palbociclib in combination with chemotherapy is safe and well-tolerated. * To learn more about side effects of palbociclib in combination with chemotherapy; * To learn more about the biological effects of palbociclib on the cells in your body
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Dexamethasone
- DRUG Palbociclib
- DRUG Bortezomib
Study Locations (1)
California
- Lucile Packard Children's Hospital Stanford - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-07-09 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04996160
The ClinicalTrials.gov registry entry for NCT04996160 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 44-participant average among 21 other Refractory Acute Lymphoblastic Leukemia trials with a reported enrollment target (50% lower). The listed sponsor is Tanja Andrea Gruber, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Refractory Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Doxorubicin is the first listed.
NCT04996160 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04996160 about?
NCT04996160 is a clinical study titled "Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)". With this research study has following goals * To confirm the highest tolerable dose of palbociclib in combination with chemotherapy is safe and well-tolerated. * To learn more about side effects of palbociclib in combination with chemotherapy; * To learn more about the biological effects of palboc...
What is the current status of trial NCT04996160?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2021-07-09. Estimated completion is 2025-12.
What conditions does trial NCT04996160 study?
This clinical trial studies the following conditions: Refractory Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT04996160?
The interventions under investigation include: Doxorubicin (DRUG), Dexamethasone (DRUG), Palbociclib (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT04996160?
This trial is sponsored by Tanja Andrea Gruber, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04996160 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 1
-
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RECRUITING · Phase 1
-
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
RECRUITING · Phase 1
-
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
RECRUITING · Phase 1
-
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
-
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
RECRUITING · Phase 1
Explore more on PlainTrial
Refractory Acute Lymphoblastic Leukemia
All registered trials for this condition
Acute Lymphoblastic Leukemia, Pediatric
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.